CA1110625A - Aminoalkylthiodibenzthiepins and related compounds, a method of preparing same and pharmaceutical and veterinary preparations including same - Google Patents
Aminoalkylthiodibenzthiepins and related compounds, a method of preparing same and pharmaceutical and veterinary preparations including sameInfo
- Publication number
- CA1110625A CA1110625A CA317,810A CA317810A CA1110625A CA 1110625 A CA1110625 A CA 1110625A CA 317810 A CA317810 A CA 317810A CA 1110625 A CA1110625 A CA 1110625A
- Authority
- CA
- Canada
- Prior art keywords
- thiepin
- formula
- beta
- ethylthio
- dibenz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 13
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 8
- 229910052736 halogen Chemical group 0.000 claims abstract description 7
- 150000002367 halogens Chemical group 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 claims description 20
- -1 cyanogen halide Chemical class 0.000 claims description 11
- 229960000583 acetic acid Drugs 0.000 claims description 10
- 239000012362 glacial acetic acid Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- MBQSJDPJRSVBGH-UHFFFAOYSA-N 3-methylsulfonyl-6h-benzo[b][1]benzothiepin-5-one Chemical compound C1C(=O)C2=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C21 MBQSJDPJRSVBGH-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims description 3
- RFEQOXYRLRIDPF-UHFFFAOYSA-N 3-chloro-6h-benzo[b][1]benzothiepin-5-one Chemical compound C1C(=O)C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RFEQOXYRLRIDPF-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- IEIUIKHMVGQHBH-UHFFFAOYSA-N 6h-benzo[b][1]benzothiepin-5-one Chemical compound O=C1CC2=CC=CC=C2SC2=CC=CC=C12 IEIUIKHMVGQHBH-UHFFFAOYSA-N 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- XLQKDTQNKRVMGD-UHFFFAOYSA-N 5,6-dihydrobenzo[b][1]benzothiepin-5-ol Chemical compound OC1CC2=CC=CC=C2SC2=CC=CC=C12 XLQKDTQNKRVMGD-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000012024 dehydrating agents Substances 0.000 claims 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- NRVFDGZJTPCULU-UHFFFAOYSA-N meda Chemical compound Cl.CN(C)CCS NRVFDGZJTPCULU-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract description 3
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 3
- 239000000935 antidepressant agent Substances 0.000 abstract description 3
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 229940005513 antidepressants Drugs 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- HELZDPUTHGTAGP-UHFFFAOYSA-N 2-[2-(4-methylsulfonylphenyl)sulfanylphenyl]acetic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1SC1=CC=CC=C1CC(O)=O HELZDPUTHGTAGP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000012259 ether extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- LJWKFGGDMBPPAZ-UHFFFAOYSA-N ethoxyethane;toluene Chemical compound CCOCC.CC1=CC=CC=C1 LJWKFGGDMBPPAZ-UHFFFAOYSA-N 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PBBDNPQCKFWBSG-UHFFFAOYSA-N n-ethyl-2-(1-nitrobenzo[b][1]benzothiepin-5-yl)sulfanylethanamine Chemical compound CCNCCSC1=CC2=CC=CC=C2SC2=C1C=CC=C2[N+]([O-])=O PBBDNPQCKFWBSG-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
- C07D337/02—Seven-membered rings
- C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D337/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D337/14—[b,f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
The present application concerns novel amino-alkylthiodibenzthiepins of the formula I
I
wherein X is hydrogen, Y is hydrogen or halogen, and Z
represent halogen or
The present application concerns novel amino-alkylthiodibenzthiepins of the formula I
I
wherein X is hydrogen, Y is hydrogen or halogen, and Z
represent halogen or
Description
l~lQ6Z5 The invention relates to novel aminoalkylthiodibenz-thiepins and related compounds and to their physiological-ly tolerable acid addition salts which are useful as anti-depressant, analgetic and anticonvulsant agents, and to pharmaceutical and veterinary compositions containing such a compound as an essential active ingredient.
It is already known that Amethoclothepine of the formula:
H V O(CH2)2N(CH3)2 ~Cl possesses central depressant activity by M. Protvia, et al.
II Farmaco XXI 98 (1966).
Japaneses Patent No. 47-28998 entitled "A Method of Manufacturing Tricyclic Compounds Having an Enolic Ether Bond" pertains to the preparation of compounds depicted by the formula O-Rl-N
~ \ R
15 in which A is an alkylimino group, an oxy radical, a thio : group or a sulfonyl group, Rl is an alkylene group, R2 and R3 each represent an alkyl group or may be bonded cyclically either through the alkylimine or not through the alkylimine group.
, ~
. .
' ~- ' ' . . ' -: , ' ': : - ' , However, the compounds of the present invention possess significant differences with respect to the aforesaid prior art compounds. Furthermore, neither reference suggests the unique methodology required for the preparation of the compounds of the present invention.
The compounds of the present invention conform to the general formula ~S- (CH2)n-Z
X~ ~ I ~
wherein X and Y are the same or different and each can be hydrogen, halogen, trifluoromethyl, C1-C6-alkoxy, C1-C6-alkyl, C1-C6alkylthio, Cl-C6alkylsulfonyl, C1-C6-alkylsul-finyl, amino or nitro, Z is halogen or N~' wherein Ris hydrogen, straight or branched chain C1-C6alkyl, cyano, cycloalkyl-C1-C6alkyl wherein the cycloalkyl ring contains from 3 to 6 carbon atoms~ phenoxycarbonyl of the formula ; -C02- ~ , C1-C6-alkoxycarbonyl, C2-C6-alkenyl or C2-C6-alkynyl, R2 is straight or branched chain C1-C6alkyl or cyc-loalkyl-C1-C6-alkyl wherein the cycloalkyl ring contains from 3 to 6 carbon atoms; and when R1 and R2 are taken to-gether with the nitrogen atom to which they are attached, the group R1-N-R2 forms a heterocycle which is morpholino, piperidino, pyrrolidinyl, or N-substituted piperazinyl in which the N-substituent is C1-C6alkyl; m is the integer O
or 1; and n is an integer of from 2 to 4; and a physiolo-gically tolerable acid addition salt thereof.
~ ~ .
.
.. . . ..
~ ~, ,:,. ~ ., . . :
.. .. . ... .: ~. .
: . : .
.. . . . . .
l~Q625 , ~, - 4 - ~OE 77/F 274 Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention lncl~lde inorganic acids such as hydrochloric, hydrobro~ic, sulfuric, nit:ric, phosphoric and perchloric acids, as well as organic 5 acids such as tartaric, citric, acetic, succinic, ~aleic, ~u~aric, and oxalic acids.
Compounds of the invention are prepared by the me'~hods given below. With the exceptions noted, X, Y, Z, R1, R2, m and n are as defined earlier.
Method a) A 10,11-dihydro-10-hydroxy- or -10-oxo-dibenz/ b,f 7 thiepin, of the Pormula .~
R3 ~ 4 X ~ Y II
wherein X and Y are as defined in formula I and R3 and R4 are different and represent each hydrogen or hydroxy or to-gether represent oxygen is reacted with aminoalkylthiol of the formula ,Rl ' HS-(cl12~ N~R2 III
wherein R1 and R2 are the same or different and each can be a straight or branched chain C1-C6alkyl to produce a com-pound of the invention of the formula Rl ' S- (CH2) R~
,, , X~S ~Y
. ~ . .
, .
.: . ' ' , :: : ~ ':, ',' : ' ~llQ6Z5 ~~ _ 5 ~ 771F 'l4 Method b) A compound prepared in Method a) wherein Rl and R2 are each methyl, can be treated with a cyano~en halide such as cyanogen bromide in a suitable solvent and acld 5 scavenger to obtain a mixture of one compound of the invention of the formula S (C~2)nhal X ~ y Ib and another compound of the invention of the formula S(CM2)n N\
X~ ~_ y , This reaction is carried out at a temperature of from about ' ambient to reflux. These two compounds of the invention may be isolated and collected by column chromato~;raphy.
Method c) A compound prepared in Method ~)of formula Ia can be reacted in a known.fashion with a suitable amine to obtain .-the corresponding compound of the invention. of the formula ~Rl ' ~S- (CH,2)n-N\R2 Ia .
,', ', ' , ' ,'' '',' '' '' "
', . ' , , ' '. ' , , ' ' ' ~ ' " ~ ' .
.
' ~11~25 wherein R is hydrogen, straight or branched chain Cl-C6al-kyl, cycloalkyl-Cl-C6alkyl, C2-C6alkenyl or Cl-C6alkynyl;
R2 is straight or branched chain C1-C6alkyl; and when Rl and R2 are taken together with the nitrogen atom to which they are attached, the group R1-N-R2 forms a heterocycle which is N-substituted piperazinyl, morpholino, piperidino or pyrrolidinyl. A preferred method is carried out with a dimethylformamide solvent, an acid scavenger such as sodium bicarbonate and a reaction initiator such as potassium iodide at a temperature of from ambient to the reflux tem-perature of the reaction mixture.
Method d) A compound prepared in Method a) 'canhe treated with a chloroformate, e.g. an alkyl or phenyl chloroformate, at a temperature of from 25 to 125C, in a solvent such as methylene chloride, toluene or benzcne to provide the corresponding compound o~ the inven~ion in w~lich Z
is N~R2 with R1 being C1-C6-alkoxy or phenoxy carbonyl.
Method e) A co~pound prepared in Methodd) is treated ~ith a base such as sodium or ~otassium hydroxide in a solvent such as water, ethanol or ethylene ~lycol at a temperature o~ ~rom ambient to reflux or with an acid medium such as hydrogen bromide in glacial acetic acid at a temperature from about ambient to reflux to provide the corresponding compound of the invention in which Rl is hydrogen.
Method f) A compound prepared in Method e is treated with a straight or branched chain C1-c6alkyl halide, C2-C6 alky-: ' , ~ , l~lQ6ZS
,_ nyl halide or cycloalkyl-Cl-C6alkyl halide under conditions normal for such reactions to provide the corresponaing com-pound of the invention in which Rl is straight or branched chain Cl c6alkyl, C2-C6alkenyl, C2-C6alkynyl or cycloalkyl-Cl-C6alkyl. A preferred method is to carry out this sub-stitution in the presence of a solvent such as dimethyl-formamide, an acid scavenger such as sodium bicarbonate and a reaction initiator such as potassium iodide at the reflux temperature of the solvent.
Method g) A compound prepared in any of the above methods, which includes a nitro group can be reduced by a convent-ional method to produce the corresponding amino compound.
As is appreciated by those skilled in the art, specific reaction conditions in any of the above methods are dependent on and are a function of the ingredients of each procedure.
The compounds of the invention are useful in the treatment of depression in mammals which is evidenced by their ability to inhibit tetrabenazine-induced depression ; in mice [International Journal of Neuropharmacology 8, 73 (1969)], a standard assay for useful antidepressant properties Compounds of the invention are furthex useful as analgesic agents due to their ability to alleviate pain in mammals which is demonstrated in the phenyl-p-quinone writing assay in mice, a standard assay for analgesia [Proc.
Soc, Exptl. Biol. Med., 95, 729 (1957)].
, .
: ' '. . ' ' ' ' ' '' .
- . : , . : .
- .: : . . . ..
': :
-~ 8 Compounds of the present invention are still further useful as anticonvulsant agents for mammals, as evidenced by the method of Woodbury, L.A. and Davenport, V.D. in Arch. Int. Pharmacodynam, Vol. 92, (1952) at pages 97-107.
These compounds are useful, as any of the above three categories of pharmaceutical agents, when administ-ered in an amount ranging from about 0.1 to 100 mg per kg of body weight per day.
Examples of compounds of the invention include:
11-[r-(dimethylamino)propylthio]-2-ethylsulfonyl-dibenz[b,f]thiepin;
ll-[~-~bromo)ethylthio]-2-methoxy-10,11-dihydrodibenz-[b,f]thiepin;
It is already known that Amethoclothepine of the formula:
H V O(CH2)2N(CH3)2 ~Cl possesses central depressant activity by M. Protvia, et al.
II Farmaco XXI 98 (1966).
Japaneses Patent No. 47-28998 entitled "A Method of Manufacturing Tricyclic Compounds Having an Enolic Ether Bond" pertains to the preparation of compounds depicted by the formula O-Rl-N
~ \ R
15 in which A is an alkylimino group, an oxy radical, a thio : group or a sulfonyl group, Rl is an alkylene group, R2 and R3 each represent an alkyl group or may be bonded cyclically either through the alkylimine or not through the alkylimine group.
, ~
. .
' ~- ' ' . . ' -: , ' ': : - ' , However, the compounds of the present invention possess significant differences with respect to the aforesaid prior art compounds. Furthermore, neither reference suggests the unique methodology required for the preparation of the compounds of the present invention.
The compounds of the present invention conform to the general formula ~S- (CH2)n-Z
X~ ~ I ~
wherein X and Y are the same or different and each can be hydrogen, halogen, trifluoromethyl, C1-C6-alkoxy, C1-C6-alkyl, C1-C6alkylthio, Cl-C6alkylsulfonyl, C1-C6-alkylsul-finyl, amino or nitro, Z is halogen or N~' wherein Ris hydrogen, straight or branched chain C1-C6alkyl, cyano, cycloalkyl-C1-C6alkyl wherein the cycloalkyl ring contains from 3 to 6 carbon atoms~ phenoxycarbonyl of the formula ; -C02- ~ , C1-C6-alkoxycarbonyl, C2-C6-alkenyl or C2-C6-alkynyl, R2 is straight or branched chain C1-C6alkyl or cyc-loalkyl-C1-C6-alkyl wherein the cycloalkyl ring contains from 3 to 6 carbon atoms; and when R1 and R2 are taken to-gether with the nitrogen atom to which they are attached, the group R1-N-R2 forms a heterocycle which is morpholino, piperidino, pyrrolidinyl, or N-substituted piperazinyl in which the N-substituent is C1-C6alkyl; m is the integer O
or 1; and n is an integer of from 2 to 4; and a physiolo-gically tolerable acid addition salt thereof.
~ ~ .
.
.. . . ..
~ ~, ,:,. ~ ., . . :
.. .. . ... .: ~. .
: . : .
.. . . . . .
l~Q625 , ~, - 4 - ~OE 77/F 274 Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention lncl~lde inorganic acids such as hydrochloric, hydrobro~ic, sulfuric, nit:ric, phosphoric and perchloric acids, as well as organic 5 acids such as tartaric, citric, acetic, succinic, ~aleic, ~u~aric, and oxalic acids.
Compounds of the invention are prepared by the me'~hods given below. With the exceptions noted, X, Y, Z, R1, R2, m and n are as defined earlier.
Method a) A 10,11-dihydro-10-hydroxy- or -10-oxo-dibenz/ b,f 7 thiepin, of the Pormula .~
R3 ~ 4 X ~ Y II
wherein X and Y are as defined in formula I and R3 and R4 are different and represent each hydrogen or hydroxy or to-gether represent oxygen is reacted with aminoalkylthiol of the formula ,Rl ' HS-(cl12~ N~R2 III
wherein R1 and R2 are the same or different and each can be a straight or branched chain C1-C6alkyl to produce a com-pound of the invention of the formula Rl ' S- (CH2) R~
,, , X~S ~Y
. ~ . .
, .
.: . ' ' , :: : ~ ':, ',' : ' ~llQ6Z5 ~~ _ 5 ~ 771F 'l4 Method b) A compound prepared in Method a) wherein Rl and R2 are each methyl, can be treated with a cyano~en halide such as cyanogen bromide in a suitable solvent and acld 5 scavenger to obtain a mixture of one compound of the invention of the formula S (C~2)nhal X ~ y Ib and another compound of the invention of the formula S(CM2)n N\
X~ ~_ y , This reaction is carried out at a temperature of from about ' ambient to reflux. These two compounds of the invention may be isolated and collected by column chromato~;raphy.
Method c) A compound prepared in Method ~)of formula Ia can be reacted in a known.fashion with a suitable amine to obtain .-the corresponding compound of the invention. of the formula ~Rl ' ~S- (CH,2)n-N\R2 Ia .
,', ', ' , ' ,'' '',' '' '' "
', . ' , , ' '. ' , , ' ' ' ~ ' " ~ ' .
.
' ~11~25 wherein R is hydrogen, straight or branched chain Cl-C6al-kyl, cycloalkyl-Cl-C6alkyl, C2-C6alkenyl or Cl-C6alkynyl;
R2 is straight or branched chain C1-C6alkyl; and when Rl and R2 are taken together with the nitrogen atom to which they are attached, the group R1-N-R2 forms a heterocycle which is N-substituted piperazinyl, morpholino, piperidino or pyrrolidinyl. A preferred method is carried out with a dimethylformamide solvent, an acid scavenger such as sodium bicarbonate and a reaction initiator such as potassium iodide at a temperature of from ambient to the reflux tem-perature of the reaction mixture.
Method d) A compound prepared in Method a) 'canhe treated with a chloroformate, e.g. an alkyl or phenyl chloroformate, at a temperature of from 25 to 125C, in a solvent such as methylene chloride, toluene or benzcne to provide the corresponding compound o~ the inven~ion in w~lich Z
is N~R2 with R1 being C1-C6-alkoxy or phenoxy carbonyl.
Method e) A co~pound prepared in Methodd) is treated ~ith a base such as sodium or ~otassium hydroxide in a solvent such as water, ethanol or ethylene ~lycol at a temperature o~ ~rom ambient to reflux or with an acid medium such as hydrogen bromide in glacial acetic acid at a temperature from about ambient to reflux to provide the corresponding compound of the invention in which Rl is hydrogen.
Method f) A compound prepared in Method e is treated with a straight or branched chain C1-c6alkyl halide, C2-C6 alky-: ' , ~ , l~lQ6ZS
,_ nyl halide or cycloalkyl-Cl-C6alkyl halide under conditions normal for such reactions to provide the corresponaing com-pound of the invention in which Rl is straight or branched chain Cl c6alkyl, C2-C6alkenyl, C2-C6alkynyl or cycloalkyl-Cl-C6alkyl. A preferred method is to carry out this sub-stitution in the presence of a solvent such as dimethyl-formamide, an acid scavenger such as sodium bicarbonate and a reaction initiator such as potassium iodide at the reflux temperature of the solvent.
Method g) A compound prepared in any of the above methods, which includes a nitro group can be reduced by a convent-ional method to produce the corresponding amino compound.
As is appreciated by those skilled in the art, specific reaction conditions in any of the above methods are dependent on and are a function of the ingredients of each procedure.
The compounds of the invention are useful in the treatment of depression in mammals which is evidenced by their ability to inhibit tetrabenazine-induced depression ; in mice [International Journal of Neuropharmacology 8, 73 (1969)], a standard assay for useful antidepressant properties Compounds of the invention are furthex useful as analgesic agents due to their ability to alleviate pain in mammals which is demonstrated in the phenyl-p-quinone writing assay in mice, a standard assay for analgesia [Proc.
Soc, Exptl. Biol. Med., 95, 729 (1957)].
, .
: ' '. . ' ' ' ' ' '' .
- . : , . : .
- .: : . . . ..
': :
-~ 8 Compounds of the present invention are still further useful as anticonvulsant agents for mammals, as evidenced by the method of Woodbury, L.A. and Davenport, V.D. in Arch. Int. Pharmacodynam, Vol. 92, (1952) at pages 97-107.
These compounds are useful, as any of the above three categories of pharmaceutical agents, when administ-ered in an amount ranging from about 0.1 to 100 mg per kg of body weight per day.
Examples of compounds of the invention include:
11-[r-(dimethylamino)propylthio]-2-ethylsulfonyl-dibenz[b,f]thiepin;
ll-[~-~bromo)ethylthio]-2-methoxy-10,11-dihydrodibenz-[b,f]thiepin;
2-ethyl-11-[~-(methylamino)ethylthio]dibenz[b,f]
thiepin;
ll-[~-(ethylmethylar,lino)ethylthio]-2-methylsulfinyl-dibenz[b,f]thiepin;
~ -(ethylmethylamino)ethylthio]-2-methylthiodibenz-i [b,f]thiepin;
10,11-dihydro-10-[~-(piperidino)ethylthio]dibenz-~b,f]thiepin;
10,11-dihydro-10-[~-(N-methylpiperazino)propylthio]-dibenz[b,f]thiepin;
10,11-dihydro-10-[~-(piperidino)-n-butylthio]dibenz-[b,f]thiepin;
10-[~-(pyrrolidino)ethylthio]dibenz[b,f]thiepin;
thiepin;
ll-[~-(ethylmethylar,lino)ethylthio]-2-methylsulfinyl-dibenz[b,f]thiepin;
~ -(ethylmethylamino)ethylthio]-2-methylthiodibenz-i [b,f]thiepin;
10,11-dihydro-10-[~-(piperidino)ethylthio]dibenz-~b,f]thiepin;
10,11-dihydro-10-[~-(N-methylpiperazino)propylthio]-dibenz[b,f]thiepin;
10,11-dihydro-10-[~-(piperidino)-n-butylthio]dibenz-[b,f]thiepin;
10-[~-(pyrrolidino)ethylthio]dibenz[b,f]thiepin;
3-chloro-11-[~-(ethylmethylamino)ethylthio]dibenz-[b,f]thiepin;
' :, . .
fi~
, ~
ll-[~-(ethylamino)ethylthio]-10,11-dihydro-4-nitrodibenz[b,f]thiepin;
ll-[~-(ethylamino)ethylthio]-3-trifluoromethyl-dibenz[b,f]thiepin 2-amino-11-[~-(ethylamino)ethylthio]dibenz[b,f]-thiepin;
ll-[~-(ethylamino)ethylthio]-3-methoxydibenz-[b,f]thiepin;
ll-[~-(diethylamino)ethylthio]-2-n-propyldibenz-[b,f]thiepin;
ll-[~-(methylamino)ethylthio]-3-methylthiodibenz-[b,f]thiepin;
8-chloro-10,11-dihydro-10-[~-(dimethylamino)ethyl-thio]-2-methyldibenz[b,f]thiepin; :
3-fluoro-11-[~-(methylamino)ethylthio]dibenz-[b,f]thiepin;
2-bror,lo-7-fluoro-11-[~-tdimethylamino)ethylthio]-: aibenz-[b,f]thiepin;
3-ethyl~ [~-(methylamino)ethylthio]dibenz[b,f]-thiepin;
11-[ -(ethylamino)ethylthio]-4-nitrodibenz-[b,f]thiepin;
2-methyl-11-~3-(N-meth~l-N-methoxycarbonylamino)-ethylthio]dibenz[b,f]thiepin;
: 25 10-[~-(N-cyclopropylmethyl-N-methylamino)ethylthio]-dibenz[b,f]thiepin;
10-[~-(N-allyl-N-methylamino)ethylthio]dibenz-[b,f]thiepin; and . :;:
6;~5 10-[~-(N-methyl-N-propargylamino)ethylthio]dibenz-[b,f~thiepin.
Effective quantities of the compoundsof the invention may be administered to a patient by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.
The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets.
For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixiers, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit.
The amount of active compound in such compositions is ; such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form ~j, '. .
contains between 1.0-300 milligrams of active compound.
The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as microcrystalline cellulose, gum tragacanth or gelatin;
an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, corn starch and the like; a lubricant such as magnesium stearate or Sterotex;
a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A
syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For the purpose of parenteral therapeutic administr-ation the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied to between 0.5% and about 30%
of the weight thereof. The amount of active compound in ' ' ' : ' ' ' ` ~ ' ~ '' ' ' ' "
' . ~ ' . ...
in suc~l compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
The solutions or suspensions may also include the following co~ponents: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampuls, disposable syringes or multiple dose vials made of glass or plastic.
Example 1 63 ml of boron trifluoride etherate are added to a solution of 20.0 g of 2-chloro-10,11-dihydro-11-oxodibenz-[b,f]thiepin, 21.8 g of ~-dimethylaminoethanethiol hydrochloride and 218 ml of glacial acetic acid. After total addition the reaction mixture is stirred for 30 minutes and then permitted to stand for 48 hours.
Thereafter, the mixture is poured into 1200 ml of a 10%
sodium hydroxide solution and the basified mixture is extracted with methylene chloride. The combined methylene chloride fractions are successi~ely washed with . ~
water, dried and filtered and the filtrate evaporated to dryness leaving a red oil. The oil is column chromato-graphed through a silica gel/methylene chloride column with a 2-4% methanol in methylene chloride mixture as the eluant. The purified product is converted to its hydrogen chloride salt of 2-chloro-11-~-(dimethylamino)-ethylthio]dibenzEb,f]thiepin hydrochloride.
Analysis:
Calculated for C18H18ClNS2-HCl: 56.24%C; 4.98~H; 3.64~N.
Found: 56.35%C; 5.17%H; 3.47%~.
Example 2 A sample of lO,ll-dihydro-lO-oxodibenz[b,r]thiepin is treated according to the manipulative procedure of Example l to provide 10-[~-(dimethylamino)ethylthio]-dibenz[b,f]thiepin hydrochloride.
Example 3 To a mixture of 1.08 g of 6-dimethylaminoethanethiol - hydrochloride and 2.5 ml of boron trifluoride etherate is added dropwise a mixture of 1.0 g of 2-chloro-lO,ll-dihydro-ll-hydroxyspirodiben~[b,f]thiepin in 8 ml of glacial acetic ; acid. After total addition, the reaction mixture is stirred at ambient temperature for 30 minutes and then permitted to stand for 24 hours. Thereafter, the reaction is poured into 50 ml of a saturated potassium carbonate-ice solution where it is extracted with ether. The combined ether extracts are, successively, washed with a dilute potassium carbonate solution and water and dried, filtered and evaporated. The resulting oil is . . ~
, . : . . . : .
' . ~: ' . . ~ .
. ,: : . ~ ' ~ : .
~1$~5 "
chror.latographed through a silica gel/methylene chloride, a 5% methyl alcohol is methylene chloride eluant and then converted to the maleic acid salt, mp, 99-101C of 2-chloro-10,11-dihydro-11-[~-tdimethylamino)-ethylchio]-dibenz[b,f]thiepin maleate.
Analysis:
Calculated or C18 20 2 C4 4 4 Found: 56.70%C; 5.29%H; 3.03%N.
Example 4 A sample of 10-E~-(dimethylamino)ethylthio]dibenz-[b,f]thiepin, free base of Example 3, is treated according to the manipulative procedure of Example 3 to provide 10, ll-dihydro-10-[~-(dimethylamino)ethylthio]dibenzlb,f]thiepin hydrochloride.
Example 5 A solution of 1.0 g of 2-chloro-11-[~-(dimethylamino) -ethylthio]dibenz[b,f]thiepin, free base of Examyle 1, in 10 ml of methylene chloride is added dropwise to a stirring solution of 0.5 g of cyanogen bromide and 1.0 g o potassium carbonate in 7 ml of methylene chloride.
After total addition, the reaction is permitted to stand with complete reaction occuring after about four hours.
After the reaction is completed the mixture is filtered and the filtrate evaporated leaving an oil. The oil is chromatographed through a silica gel/methylene chloride column with methylene chloride as the eluant.
The desired fraction is evaporated to dryness leaving : ~ .
:- .
.Q6Z~;
2-chloro-11-[~-(N-cyano-l~-methyl)ar.~inoethylthio]dibenz(b,f]-thiepin, as a yellow oil -Analysis:
Calculated for C18H15ClN2 2 6 3%C;
Found: 60.62%C; 4.19%H; 7.75%N.
Example 6 To a stirring solution of 0.50 g of phenyl chloroformate and 0.2 g of sodium bicarbonate in 20 ml of methylene chloride is added dropwise a solution of 0.95 g of 2-chloro-11-[~-(dimethylamino)ethylthio]dibenz-[b,f]thiepin, free base of Example 1, in 10 ml of methylene chloride. After total addition the reaction is successively stirred at 25C for 24 hours, filtered, diluted with 25 rnl of methylene chloride, washed with a 10% sodium hydroxide solution, washed with water, dried and filtered. The filtrate is evaporated leaving a yellow oil which is chromatographed through a silica gel/methylene chloride column with methylene chloride as the eluant.
The purified product is the yellow oil of 2-chloro-11-[~-(N-methyl-N-phenoxycarbonylamino)-ethylthio]dibenz[b,f]-thiepin.
Analysis:
Calculated for C24H20ClNO2S2: 63.49~C; 4.44%H; 3.09%N.
Found: 63.76%C; 4.49~H; 2.90%N.
In a similar fashion a sample of 10-[~-(dimethyl-amino)ethylthio]dibenz[b,f]thiepin, free base of Example 2, is treated to provide 10-[~-(N-methyl-N-phenoxycarbonyl-amino)-ethylthio]dibenz[b,f]thiepin.
,, ..: . . .. . , :
. :: . :.' '. ~ ,;
6; :5 Example 7 A solution of 5.6 g of 2-chloro~ll-[~-(N-methyl-N-phenoxycarbonylamino)ethylthio]dibenz[b,f]thiepin, Example 6, 127 ml of ethylene gylcol and 10.8 g of potassium hydroxide is stirred at 150-155C for 30 minutes.
Thereafter the reaction mixture is poured onto 300 ml of ice-water and the aqueous mixture is extracted with an ether-toluene (1:1) mixture. The combined extracts, successively, are washed well with water, dried and filtered and the filtrate evaporated leaving an orange oil. The oil is converted to its hydrogen chloride acid salt which is recrystallized from a methanol-acetone-ether mixture to give the product, mp 194-196C of 2-chloro-11-[~-(methylamino)ethylthio]dibenz[b,f]thiepin hydrochloride.
Analysis:
Calculated for C17H16ClNS2 ~Cl: 55.13%C; 4.63%H; 3.78%N.
Found: 55.28%C; 4.71%H; 3.93%1~.
In a similar fashion, 10-[~-(N-methyl-N-phenoxycarbonylamino)ethylthio]dibenz[b,f]thiepin,hereinabove described, is treated to provide 10-[~-(methyl-amino)ethylthio]dibenz[b,f]thiepin hydrochloride.
Example 8 A solution of 2-chloro-lO,ll~dihydro-ll-[~-dimethyl-ar.lino)ethylthio]dibenz[b,f]thiepin, free base of Example3, in 10 ml of chloroform is added dropwise to a solution of a stoichiometric amount of cyanogen bromide and an excess amount of potassium carbonate in 5 ml of chloroform.
6Z~
,,~~ . .
After total addition the reaction mixture is permitted to stand for 10 minutes and then filtered. The filtrate is concentrated to dryness leaving the product 11~
brornoethylthio)-2-chloro-10,11-dihydrodibenz[b,f]thiepin.
Example 9 A mixture of stoichiometric amounts of 2-chloro-11-(~-bromoethylthio)-10,11-dihydrodibenz[b,f]thiepin, Example 8, and N-methylpiperzine, an excess amount of sodium bicarbonate, and 1.0 g of potassium iodide in 15 ml of dimethylformamide is stirred at 80C for 16 hours.
The mixture is permitted to cool before being diluted with water. The biphasic mixture is extracted thrice with 100 ml portions of ether, the ether extracts are combined and shaken vigorously with a large excess of 2N hydro-chloric acid. The acidic solution is basified, liberating the free amine which is extracted into benzene. The benzene solution is dried and the benzene removed under vacuum, leaving the product 2-chloro-10,11-dihydro-11[~-(4-methylpiperazinyl-1-yl)ethylthio]dibenz[b,f]thiepin.
In a similar fashion, substituting morpholine for N-methylpiperazine provides 2-chloro-10,11-dihydro-11-(~-morpholinoethylthio)dibenz[b,f]thiepin.
Examples 10 & 11 By following the manipulative procedure of Example 2, respectively substituting ~-diisopropylaminoethanethiol hydrochloride, ~-diethylaminoethanethiol hydrochloride for ~-dimethylaminoethanethiol hydrochloride provides Example 10, 10-[~-(diisopropylamino)ethylthio]dibenz[b,f]-.
': ' " "'. ~.` : ' ,' . ' .~ . ., ~, . . ........................... .
, . ~ . . .
~ 625 1~
thiepin hydrochloride and Example 11, 10~[~-(diethylamino)-ethylthio]dibenz[b,f]thiepin hydrochloride.
Example 12 a. A solution of stoichiometric amounts of 2-(4-methylsulfonylphenylthio)benzyl nitrile and 85% potassium hydroxide in an alcohol-water mixture is stirred at 115C
for 24 hours, Thereafter the reaction mixture is concen-trated to an oil. The oil is dissolved in water and the aqueous solution is successively, washed ~.ith ether, acidified with dilute hydrochloric acid again providing an oil. This oil is dissolved in methylene chloride and the solution, successively, is dried, filtered and concentrated to dryness leaving the product 2-(4-methyl-sulfonylphenylthio)phenylacetic acid.
b. A mixture of 1.0 g of 2-(4-methylsulfonyl-phenylthio)phenyl acetic acid and 10 ml of polyphosphoric acid under nitrogen is stirred at ~0-100C for 2 hours.
The reaction mixture is permitted to cool and then poured into 100 ml of ice-water slurry. The aqueous solution is basified with 20% sodium hydroxide before being extracted with rnethylene chloride. The combined extracts are dried and then evaporated to dryness leaving an oil. The oil is chromatographed through a silica gel column with a 2%
methanol in methylene chloride eluant. The chromatographed solution is evaporated to dryness providing 10,11-dihydro-2-methylsulfonyl-ll-oxodibenz[b,f]thiepin.
.
.: ~
~ .
, c. A solution of stoichiometric amounts o 10,11-dihydro-2-methylsulfonyl-11-oxodibenz[b,f]thiepin and dirnethylaminoethanethiol hydrochloride and 15 ml of boron trifluoride etherate in 37 ml of glacial acetic acid is stirred until reaction is completed. Thereafter the reaction mixture is poured into 300 ml of a cold sodium hydroxide solution and the resulting solution is extracted with methylene chloride. The combined extracts are washed with water and dried before being filtered. The filtrate is evaporated to dryness leaving an oil which is chromatographed through a silica gel/methylene chloride column with methanol (2-4~) in methylene chloride eluant.
The chromatographed solution is evaporated to dryness leaving ll-[(~-dimethylamino)ethylthio]-2-methylsulonyldi-benz[b,f]thiepin.
.: ~ .
' ' ' ~ .
.. . . . . .. . . .
.
' :, . .
fi~
, ~
ll-[~-(ethylamino)ethylthio]-10,11-dihydro-4-nitrodibenz[b,f]thiepin;
ll-[~-(ethylamino)ethylthio]-3-trifluoromethyl-dibenz[b,f]thiepin 2-amino-11-[~-(ethylamino)ethylthio]dibenz[b,f]-thiepin;
ll-[~-(ethylamino)ethylthio]-3-methoxydibenz-[b,f]thiepin;
ll-[~-(diethylamino)ethylthio]-2-n-propyldibenz-[b,f]thiepin;
ll-[~-(methylamino)ethylthio]-3-methylthiodibenz-[b,f]thiepin;
8-chloro-10,11-dihydro-10-[~-(dimethylamino)ethyl-thio]-2-methyldibenz[b,f]thiepin; :
3-fluoro-11-[~-(methylamino)ethylthio]dibenz-[b,f]thiepin;
2-bror,lo-7-fluoro-11-[~-tdimethylamino)ethylthio]-: aibenz-[b,f]thiepin;
3-ethyl~ [~-(methylamino)ethylthio]dibenz[b,f]-thiepin;
11-[ -(ethylamino)ethylthio]-4-nitrodibenz-[b,f]thiepin;
2-methyl-11-~3-(N-meth~l-N-methoxycarbonylamino)-ethylthio]dibenz[b,f]thiepin;
: 25 10-[~-(N-cyclopropylmethyl-N-methylamino)ethylthio]-dibenz[b,f]thiepin;
10-[~-(N-allyl-N-methylamino)ethylthio]dibenz-[b,f]thiepin; and . :;:
6;~5 10-[~-(N-methyl-N-propargylamino)ethylthio]dibenz-[b,f~thiepin.
Effective quantities of the compoundsof the invention may be administered to a patient by any one of various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.
The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets.
For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixiers, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit.
The amount of active compound in such compositions is ; such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form ~j, '. .
contains between 1.0-300 milligrams of active compound.
The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as microcrystalline cellulose, gum tragacanth or gelatin;
an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, corn starch and the like; a lubricant such as magnesium stearate or Sterotex;
a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A
syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For the purpose of parenteral therapeutic administr-ation the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied to between 0.5% and about 30%
of the weight thereof. The amount of active compound in ' ' ' : ' ' ' ` ~ ' ~ '' ' ' ' "
' . ~ ' . ...
in suc~l compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
The solutions or suspensions may also include the following co~ponents: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampuls, disposable syringes or multiple dose vials made of glass or plastic.
Example 1 63 ml of boron trifluoride etherate are added to a solution of 20.0 g of 2-chloro-10,11-dihydro-11-oxodibenz-[b,f]thiepin, 21.8 g of ~-dimethylaminoethanethiol hydrochloride and 218 ml of glacial acetic acid. After total addition the reaction mixture is stirred for 30 minutes and then permitted to stand for 48 hours.
Thereafter, the mixture is poured into 1200 ml of a 10%
sodium hydroxide solution and the basified mixture is extracted with methylene chloride. The combined methylene chloride fractions are successi~ely washed with . ~
water, dried and filtered and the filtrate evaporated to dryness leaving a red oil. The oil is column chromato-graphed through a silica gel/methylene chloride column with a 2-4% methanol in methylene chloride mixture as the eluant. The purified product is converted to its hydrogen chloride salt of 2-chloro-11-~-(dimethylamino)-ethylthio]dibenzEb,f]thiepin hydrochloride.
Analysis:
Calculated for C18H18ClNS2-HCl: 56.24%C; 4.98~H; 3.64~N.
Found: 56.35%C; 5.17%H; 3.47%~.
Example 2 A sample of lO,ll-dihydro-lO-oxodibenz[b,r]thiepin is treated according to the manipulative procedure of Example l to provide 10-[~-(dimethylamino)ethylthio]-dibenz[b,f]thiepin hydrochloride.
Example 3 To a mixture of 1.08 g of 6-dimethylaminoethanethiol - hydrochloride and 2.5 ml of boron trifluoride etherate is added dropwise a mixture of 1.0 g of 2-chloro-lO,ll-dihydro-ll-hydroxyspirodiben~[b,f]thiepin in 8 ml of glacial acetic ; acid. After total addition, the reaction mixture is stirred at ambient temperature for 30 minutes and then permitted to stand for 24 hours. Thereafter, the reaction is poured into 50 ml of a saturated potassium carbonate-ice solution where it is extracted with ether. The combined ether extracts are, successively, washed with a dilute potassium carbonate solution and water and dried, filtered and evaporated. The resulting oil is . . ~
, . : . . . : .
' . ~: ' . . ~ .
. ,: : . ~ ' ~ : .
~1$~5 "
chror.latographed through a silica gel/methylene chloride, a 5% methyl alcohol is methylene chloride eluant and then converted to the maleic acid salt, mp, 99-101C of 2-chloro-10,11-dihydro-11-[~-tdimethylamino)-ethylchio]-dibenz[b,f]thiepin maleate.
Analysis:
Calculated or C18 20 2 C4 4 4 Found: 56.70%C; 5.29%H; 3.03%N.
Example 4 A sample of 10-E~-(dimethylamino)ethylthio]dibenz-[b,f]thiepin, free base of Example 3, is treated according to the manipulative procedure of Example 3 to provide 10, ll-dihydro-10-[~-(dimethylamino)ethylthio]dibenzlb,f]thiepin hydrochloride.
Example 5 A solution of 1.0 g of 2-chloro-11-[~-(dimethylamino) -ethylthio]dibenz[b,f]thiepin, free base of Examyle 1, in 10 ml of methylene chloride is added dropwise to a stirring solution of 0.5 g of cyanogen bromide and 1.0 g o potassium carbonate in 7 ml of methylene chloride.
After total addition, the reaction is permitted to stand with complete reaction occuring after about four hours.
After the reaction is completed the mixture is filtered and the filtrate evaporated leaving an oil. The oil is chromatographed through a silica gel/methylene chloride column with methylene chloride as the eluant.
The desired fraction is evaporated to dryness leaving : ~ .
:- .
.Q6Z~;
2-chloro-11-[~-(N-cyano-l~-methyl)ar.~inoethylthio]dibenz(b,f]-thiepin, as a yellow oil -Analysis:
Calculated for C18H15ClN2 2 6 3%C;
Found: 60.62%C; 4.19%H; 7.75%N.
Example 6 To a stirring solution of 0.50 g of phenyl chloroformate and 0.2 g of sodium bicarbonate in 20 ml of methylene chloride is added dropwise a solution of 0.95 g of 2-chloro-11-[~-(dimethylamino)ethylthio]dibenz-[b,f]thiepin, free base of Example 1, in 10 ml of methylene chloride. After total addition the reaction is successively stirred at 25C for 24 hours, filtered, diluted with 25 rnl of methylene chloride, washed with a 10% sodium hydroxide solution, washed with water, dried and filtered. The filtrate is evaporated leaving a yellow oil which is chromatographed through a silica gel/methylene chloride column with methylene chloride as the eluant.
The purified product is the yellow oil of 2-chloro-11-[~-(N-methyl-N-phenoxycarbonylamino)-ethylthio]dibenz[b,f]-thiepin.
Analysis:
Calculated for C24H20ClNO2S2: 63.49~C; 4.44%H; 3.09%N.
Found: 63.76%C; 4.49~H; 2.90%N.
In a similar fashion a sample of 10-[~-(dimethyl-amino)ethylthio]dibenz[b,f]thiepin, free base of Example 2, is treated to provide 10-[~-(N-methyl-N-phenoxycarbonyl-amino)-ethylthio]dibenz[b,f]thiepin.
,, ..: . . .. . , :
. :: . :.' '. ~ ,;
6; :5 Example 7 A solution of 5.6 g of 2-chloro~ll-[~-(N-methyl-N-phenoxycarbonylamino)ethylthio]dibenz[b,f]thiepin, Example 6, 127 ml of ethylene gylcol and 10.8 g of potassium hydroxide is stirred at 150-155C for 30 minutes.
Thereafter the reaction mixture is poured onto 300 ml of ice-water and the aqueous mixture is extracted with an ether-toluene (1:1) mixture. The combined extracts, successively, are washed well with water, dried and filtered and the filtrate evaporated leaving an orange oil. The oil is converted to its hydrogen chloride acid salt which is recrystallized from a methanol-acetone-ether mixture to give the product, mp 194-196C of 2-chloro-11-[~-(methylamino)ethylthio]dibenz[b,f]thiepin hydrochloride.
Analysis:
Calculated for C17H16ClNS2 ~Cl: 55.13%C; 4.63%H; 3.78%N.
Found: 55.28%C; 4.71%H; 3.93%1~.
In a similar fashion, 10-[~-(N-methyl-N-phenoxycarbonylamino)ethylthio]dibenz[b,f]thiepin,hereinabove described, is treated to provide 10-[~-(methyl-amino)ethylthio]dibenz[b,f]thiepin hydrochloride.
Example 8 A solution of 2-chloro-lO,ll~dihydro-ll-[~-dimethyl-ar.lino)ethylthio]dibenz[b,f]thiepin, free base of Example3, in 10 ml of chloroform is added dropwise to a solution of a stoichiometric amount of cyanogen bromide and an excess amount of potassium carbonate in 5 ml of chloroform.
6Z~
,,~~ . .
After total addition the reaction mixture is permitted to stand for 10 minutes and then filtered. The filtrate is concentrated to dryness leaving the product 11~
brornoethylthio)-2-chloro-10,11-dihydrodibenz[b,f]thiepin.
Example 9 A mixture of stoichiometric amounts of 2-chloro-11-(~-bromoethylthio)-10,11-dihydrodibenz[b,f]thiepin, Example 8, and N-methylpiperzine, an excess amount of sodium bicarbonate, and 1.0 g of potassium iodide in 15 ml of dimethylformamide is stirred at 80C for 16 hours.
The mixture is permitted to cool before being diluted with water. The biphasic mixture is extracted thrice with 100 ml portions of ether, the ether extracts are combined and shaken vigorously with a large excess of 2N hydro-chloric acid. The acidic solution is basified, liberating the free amine which is extracted into benzene. The benzene solution is dried and the benzene removed under vacuum, leaving the product 2-chloro-10,11-dihydro-11[~-(4-methylpiperazinyl-1-yl)ethylthio]dibenz[b,f]thiepin.
In a similar fashion, substituting morpholine for N-methylpiperazine provides 2-chloro-10,11-dihydro-11-(~-morpholinoethylthio)dibenz[b,f]thiepin.
Examples 10 & 11 By following the manipulative procedure of Example 2, respectively substituting ~-diisopropylaminoethanethiol hydrochloride, ~-diethylaminoethanethiol hydrochloride for ~-dimethylaminoethanethiol hydrochloride provides Example 10, 10-[~-(diisopropylamino)ethylthio]dibenz[b,f]-.
': ' " "'. ~.` : ' ,' . ' .~ . ., ~, . . ........................... .
, . ~ . . .
~ 625 1~
thiepin hydrochloride and Example 11, 10~[~-(diethylamino)-ethylthio]dibenz[b,f]thiepin hydrochloride.
Example 12 a. A solution of stoichiometric amounts of 2-(4-methylsulfonylphenylthio)benzyl nitrile and 85% potassium hydroxide in an alcohol-water mixture is stirred at 115C
for 24 hours, Thereafter the reaction mixture is concen-trated to an oil. The oil is dissolved in water and the aqueous solution is successively, washed ~.ith ether, acidified with dilute hydrochloric acid again providing an oil. This oil is dissolved in methylene chloride and the solution, successively, is dried, filtered and concentrated to dryness leaving the product 2-(4-methyl-sulfonylphenylthio)phenylacetic acid.
b. A mixture of 1.0 g of 2-(4-methylsulfonyl-phenylthio)phenyl acetic acid and 10 ml of polyphosphoric acid under nitrogen is stirred at ~0-100C for 2 hours.
The reaction mixture is permitted to cool and then poured into 100 ml of ice-water slurry. The aqueous solution is basified with 20% sodium hydroxide before being extracted with rnethylene chloride. The combined extracts are dried and then evaporated to dryness leaving an oil. The oil is chromatographed through a silica gel column with a 2%
methanol in methylene chloride eluant. The chromatographed solution is evaporated to dryness providing 10,11-dihydro-2-methylsulfonyl-ll-oxodibenz[b,f]thiepin.
.
.: ~
~ .
, c. A solution of stoichiometric amounts o 10,11-dihydro-2-methylsulfonyl-11-oxodibenz[b,f]thiepin and dirnethylaminoethanethiol hydrochloride and 15 ml of boron trifluoride etherate in 37 ml of glacial acetic acid is stirred until reaction is completed. Thereafter the reaction mixture is poured into 300 ml of a cold sodium hydroxide solution and the resulting solution is extracted with methylene chloride. The combined extracts are washed with water and dried before being filtered. The filtrate is evaporated to dryness leaving an oil which is chromatographed through a silica gel/methylene chloride column with methanol (2-4~) in methylene chloride eluant.
The chromatographed solution is evaporated to dryness leaving ll-[(~-dimethylamino)ethylthio]-2-methylsulonyldi-benz[b,f]thiepin.
.: ~ .
' ' ' ~ .
.. . . . . .. . . .
.
Claims (16)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the preparation of a compound of the formula I
I
wherein Z is hydrogen, Y is hydrogen, halogen or methylsulfonyl, and X represents halogen or wherein R1 is hydrogen, lower alkyl, cyano or phenoxycarbonyl and R2is lower alkyl, or R1-N-R2 forms a morpholino or a N-lower alkyl substituted piper-azinyl; m is the integer 0 or 1; and n is an integer of from 2 to 4; and the physiologically tolerable acid addition salts thereof, in which a) a compound of the formula II
II
wherein X and Y are as defined in formula I and R3 and R4 are different and each is hydrogen or hydroxy, or R3 and R4 together are oxygen, is reacted with aminoalkylthiol of the formula wherein R1 and R2 are the same or different and each represents lower alkyl in the presence of a catalyst/dehydrating agent and a solvent to produce a compound of the formula Ia Ia or b) a compound of the formula Ia wherein R1 and R2 are each methyl is reacted with cyanogen halide to obtain a mixture of one compound of the formula Ib Ib and another compound of the formula Ic Ic wherein X, Y, m and n are as defined in the formula I and hal is halogen, and each of the two compounds is isolated; or c) a compound of the formula Ib is reacted with an appropriate non-cyclic or cyclic amine to obtain the corresponding compound of the formula Ia Ia wherein X, Y, R1, R2, m and n are as defined in formula I; or d) a compound of the formula Ia, wherein R1 and R2 are the same or different and each is lower alkyl, and X, Y, m, n are as defined in the formula I is reacted with an alkyl or phenyl chloroformate to obtain a compound of the formula Ia wherein R1 is alkoxy or phenoxy carbonyl and R2, X, Y, m and n are as defined in formula I, or e) a compound of the formula Ia, wherein X, Y, m and n are as defined in formula I, R1 is lower alkoxy or phenoxy carbonyl and R2 is a lower alkyl, is reacted with a base or an acid medium to obtain a compound of the formula Ia wherein X, Y, m and n are as defined in the formula I, R2 is as defined above and R1 is hydrogen; or f) a compound of the formula Ia, wherein X, Y, m and n are as defined in formula I, R1 is hydrogen and R2 is lower alkyl is reacted with a lower alkyl halide, to obtain a compound of the formula Ia in which X, Y, m and n are as defined in the formula I, R1 is lower alkyl, and R2 is lower alkyl.
I
wherein Z is hydrogen, Y is hydrogen, halogen or methylsulfonyl, and X represents halogen or wherein R1 is hydrogen, lower alkyl, cyano or phenoxycarbonyl and R2is lower alkyl, or R1-N-R2 forms a morpholino or a N-lower alkyl substituted piper-azinyl; m is the integer 0 or 1; and n is an integer of from 2 to 4; and the physiologically tolerable acid addition salts thereof, in which a) a compound of the formula II
II
wherein X and Y are as defined in formula I and R3 and R4 are different and each is hydrogen or hydroxy, or R3 and R4 together are oxygen, is reacted with aminoalkylthiol of the formula wherein R1 and R2 are the same or different and each represents lower alkyl in the presence of a catalyst/dehydrating agent and a solvent to produce a compound of the formula Ia Ia or b) a compound of the formula Ia wherein R1 and R2 are each methyl is reacted with cyanogen halide to obtain a mixture of one compound of the formula Ib Ib and another compound of the formula Ic Ic wherein X, Y, m and n are as defined in the formula I and hal is halogen, and each of the two compounds is isolated; or c) a compound of the formula Ib is reacted with an appropriate non-cyclic or cyclic amine to obtain the corresponding compound of the formula Ia Ia wherein X, Y, R1, R2, m and n are as defined in formula I; or d) a compound of the formula Ia, wherein R1 and R2 are the same or different and each is lower alkyl, and X, Y, m, n are as defined in the formula I is reacted with an alkyl or phenyl chloroformate to obtain a compound of the formula Ia wherein R1 is alkoxy or phenoxy carbonyl and R2, X, Y, m and n are as defined in formula I, or e) a compound of the formula Ia, wherein X, Y, m and n are as defined in formula I, R1 is lower alkoxy or phenoxy carbonyl and R2 is a lower alkyl, is reacted with a base or an acid medium to obtain a compound of the formula Ia wherein X, Y, m and n are as defined in the formula I, R2 is as defined above and R1 is hydrogen; or f) a compound of the formula Ia, wherein X, Y, m and n are as defined in formula I, R1 is hydrogen and R2 is lower alkyl is reacted with a lower alkyl halide, to obtain a compound of the formula Ia in which X, Y, m and n are as defined in the formula I, R1 is lower alkyl, and R2 is lower alkyl.
2. A compound of the formula I as defined in claim 1, whenever obtained according to a process as claimed in claim 1 or by an obvious chemical equivalent thereof.
3. A process for the preparation of 2-chloro-11-[.beta.-(dimethylamino)ethylthio]dibenz[b,f]thiepin hydrochloride in which 2-chloro-10,11-dihydro-11-oxodibenz[b,f]thiepin is reacted with .beta.-dimethylaminoethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, the product is isolated, treated with hydrochloric acid and the resultant product is subsequently isolated.
4. 2-Chloro-11-[.beta.-(dimethylamino)ethylthio]dibenz[b,f]-thiepin hydrochloride, whenever obtained according to a process as claimed in claim 3 or by an obvious chemical equivalent thereof.
5. A process for the preparation of 10-[.beta.-(dimethylamino)-ethylthio]dibenz[b,f]thiepin hydrochloride in which 10,11-dihydro-10-oxodibenz[b,f]thiepin is reacted with .beta.-dimethylaminoethane-thiol hydrochloride in the presence of boron trifluoride etherate and glacial acetic acid, the product is isolated, treated with hydrochloric acid and the resultant product is subsequently isolated.
6. 10-[.beta.-(Dimethylamino)ethylthio]dibenz[b,f]thiepin hydrochloride, whenever obtained according to a process as claimed in claim 5 or by an obvious chemical equivalent thereof.
7. A process for the preparation of 2-chloro-10,11-dihydro-11-[.beta.-(dimethylamino)ethylthio ]dibenz[b,f]thiepin maleate in which 2-chloro-10,11-dihydro-11-hydroxyspirodibenz[b,f]thiepin is reacted with .beta.-dimethylaminoethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, the product is isolated, treated with maleic acid and the resultant product is subsequently isoiated.
8. 2-Chloro-10,11-dihydro-11-[.beta.-(dimethylamino)ethylthio]-dibenz[b,f]thiepin maleate, whenever obtained according to a process as claimed in claim 7 or by an obvious chemical equivalent thereof.
9. A process for the preparation of 10,11-dihydro-10-[.beta.-(dimethylamino)ethylthio]dibenz[b,f]thiepin hydrochloride in which 10,11-dihydro-10-hydroxydibenz[b,f]thiepin, is reacted with .beta.-dimethylaminoethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, the product is isolated, treated with hydrochloric acid and the resultant product is subsequently isolated.
10. 10,11-Dihydro-10-[.beta.-(dimethylamino)ethylthio]dibenz-[b,f]thiepin hydrochloride, whenever obtained according to a process as claimed in claim 9 or by an obvious chemical equivalent thereof.
11. A process for the preparation of 11-(.beta.-bromoethylthio)-2-chloro-10,11-dihydrodibenz[b,f]thiepin in which 2-chloro-10,11-dihydro-11-hydroxyspirodibenz[b,f]thiepin is reacted with .beta.-dimethylaminoethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, 2-chloro-10,11-dihydro-11-[.beta.-(dimethylamino)ethylthio]dibenz[b,f]thiepin is isolated, dissolved in chloroform, the resultant solution is added to a solution of a stoichiometric amount of cyanogen bromide and an excess of potassium chloride in chloroform and the resultant product is subsequently isolated.
12. 11-(.beta.-Bromoethylthio)-2-chloro-10,11-dihydrodibenz-[b,f]thiepin, whenever obtained according to a process as claimed in claim 11 or by an obvious chemical equivalent thereof.
13. A process for the preparation of 1-[.beta.-dimethylamino)-ethylthio]-2-methylsulfonyldibenz[b,f]thiepin in which 10,11-dihydro-2-methylsulfonyl-11-oxodibenz[b,f]thiepin is reacted with dimethylaminoethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, and the resultant product is subsequently isolated.
14. 11-[(.beta.-Dimethylamino)ethylthio]-2-methylsulfonyldibenz-[b,f]thiepin, whenever obtained according to a process as claimed in claim 13 or by an obvious chemical equivalent thereof.
15. A process for the preparation of 10-[.beta.-(methylamino)-ethylthio]dibenz[b,f]thiepin hydrochloride in which 10,11-dihydro-10-oxodibenz[b,f]thiepin is reacted with .beta.-dimethylamino-ethanethiol hydrochloride in the presence of boron trifluoride etherate in glacial acetic acid, a solution of the resultant 10-[.beta.-(dimethylamino)ethylthio]dibenz[b,f]thiepin hydrochloride in ethylene glycol and potassium hydroxide is stirred, the product is isolated, treated with hydrochloric acid and the resultant product is subsequently isolated.
16. 10-[.beta.-(Methylamino)-ethylthio]dibenz[b,f]thiepin hydro-chloride, whenever obtained according to a process as claimed in claim 15 or by an obvious chemical equivalent thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86008277A | 1977-12-13 | 1977-12-13 | |
| US860,082 | 1977-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1110625A true CA1110625A (en) | 1981-10-13 |
Family
ID=25332450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA317,810A Expired CA1110625A (en) | 1977-12-13 | 1978-12-12 | Aminoalkylthiodibenzthiepins and related compounds, a method of preparing same and pharmaceutical and veterinary preparations including same |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0002500B1 (en) |
| JP (1) | JPS5498794A (en) |
| AT (1) | AT369740B (en) |
| CA (1) | CA1110625A (en) |
| DE (1) | DE2862219D1 (en) |
| ES (6) | ES475769A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008096755A1 (en) * | 2007-02-07 | 2008-08-14 | Nippon Suisan Kaisha, Ltd. | Vanilloid receptor (vr1) inhibitor and use thereof |
-
1978
- 1978-12-06 ES ES475769A patent/ES475769A1/en not_active Expired
- 1978-12-07 EP EP78101593A patent/EP0002500B1/en not_active Expired
- 1978-12-07 DE DE7878101593T patent/DE2862219D1/en not_active Expired
- 1978-12-12 CA CA317,810A patent/CA1110625A/en not_active Expired
- 1978-12-12 AT AT0883878A patent/AT369740B/en not_active IP Right Cessation
- 1978-12-13 JP JP15908878A patent/JPS5498794A/en active Granted
-
1979
- 1979-06-01 ES ES481186A patent/ES481186A1/en not_active Expired
- 1979-06-01 ES ES481187A patent/ES481187A1/en not_active Expired
- 1979-06-01 ES ES481188A patent/ES481188A1/en not_active Expired
- 1979-06-01 ES ES481185A patent/ES481185A1/en not_active Expired
- 1979-06-01 ES ES481189A patent/ES481189A1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES481189A1 (en) | 1980-09-01 |
| ES481187A1 (en) | 1980-08-16 |
| JPS633860B2 (en) | 1988-01-26 |
| ES475769A1 (en) | 1980-01-16 |
| JPS5498794A (en) | 1979-08-03 |
| ATA883878A (en) | 1982-06-15 |
| DE2862219D1 (en) | 1983-05-05 |
| AT369740B (en) | 1983-01-25 |
| ES481185A1 (en) | 1980-08-16 |
| ES481188A1 (en) | 1980-08-16 |
| ES481186A1 (en) | 1980-08-16 |
| EP0002500B1 (en) | 1983-03-30 |
| EP0002500A1 (en) | 1979-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4737495A (en) | (2H)-3-benzazepin-2-ones, their pharmaceutical compositions and their pharmaceutical uses | |
| US3420851A (en) | Novel dibenzoxepines | |
| EP0096838B1 (en) | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines, a process for preparing the same and their use as medicaments | |
| HU211575A9 (en) | 2-methyl-thieno-benzodiazepine | |
| SK88196A3 (en) | Novel heterocyclic compounds | |
| HU205744B (en) | Process for producing substituted benzazepines and pharmaceutical compositions comprising same | |
| US3928356A (en) | 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof | |
| JPS61115082A (en) | Tricyclic pyridine derivative | |
| FI67697B (en) | PROCEDURE FOR THE PHARMACOLOGICAL PROPERTIES OF 5-STATIONARY SUBSTITUTES 5,10-DIHYDRO-11H-DIBENZO- (B, E) (1,4) DIAZEPIN-11-ONER | |
| HU193250B (en) | Process for producing 5,11-dihydro-6h-dibenz/b,e/azepin-6-ones | |
| US4002632A (en) | Tetracyclic piperidino derivatives | |
| EP0259930B1 (en) | Derivatives of phenyl, pyrrolidin-2-yl substituted 5-ring heterocycles having antipsychotic properties | |
| CA1110625A (en) | Aminoalkylthiodibenzthiepins and related compounds, a method of preparing same and pharmaceutical and veterinary preparations including same | |
| DK160047B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 3-IMINO-DIBENZOOEC, FAAIMIDAZOOE1,5-AAAAZEPINES AND -DIBENZOOEB, FAAIMIDAZOOE1,5-DAAOE1,4AAOXAZEPINES AND THIAZEPINES | |
| DK169239B1 (en) | Pyrrolo [1,2-a] [4,1] benzoxazepines and their salts, their preparation and pharmaceutical preparations containing them | |
| US4668695A (en) | Aminoalkylthiodibenzothiepins | |
| US4237135A (en) | 2-(4-Ethyl-1-piperazinyl)-4-phenylquinoline, process for preparation thereof, and composition thereof | |
| IE44228B1 (en) | A 3-/2-/4(10,11-dihydro-dibenzo/b,f/thiepin-10-yl)-1-piperazinyl/-ethyl/-2-oxazolidinone and salts thereof | |
| IE45884B1 (en) | Benzo-fused xanthenes, thioxanthenes, and dibenzoxepins and processes for their preparation | |
| US4766143A (en) | Haloalkylthiodibenzothiepins | |
| KR810002069B1 (en) | Process for preparing aminoalkylihiodibenzthiepin compounds | |
| US4775683A (en) | Aminoalkylthiodibenzothiepins | |
| US4771069A (en) | Aminoalkylthiodibenzothiepins | |
| US4775682A (en) | Haloalkylthiodibenzothiepins | |
| US4775672A (en) | Aminoalkylthiodibenzothiepins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |